Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (2): 7-14.doi: 10.6040/j.issn.1673-3770.0.2021.318

Previous Articles     Next Articles

A case of middle-ear anaplastic large T- cell lymphoma and literature review

ZHAO Xiaobing,ZHANG Dawei, CHEN Renjie   

  1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, China
  • Published:2022-04-15

Abstract: Objective To investigate the clinical characteristics, diagnosis and treatment methods of middle ear anaplastic large T-cell lymphoma, to enable its early diagnosis. Methods A patient with middle ear anaplastic large T-cell lymphoma was retrospectively reviewed,along with previous cases of middle ear lymphoma found in the literature. Results Lymphoma mostly occurs in the bones, bone marrow, subcutaneous tissue and spleen, but rarely in the middle ear. There is no superficial lymphadenopathy at the onset of middle ear lymphoma, which usually presents as earache, hearing loss, and ear discharge(serous, purulent, or bloody). Disease progression, peripheral facial nerve paralysis and extra cranial-intracranial complications may occur. The lesion appeared as a high and uneven soft tissue density on the CT and the bone destruction was irregular and worm-eaten. The lesion area was wide and the enhanced scan showed obvious enhancement. Diagnosis requires pathological biopsy and immunohistochemistry. Chemotherapy is the main treatment. Conclusion Middle ear anaplastic large T-cell lymphoma is extremely rare and its clinical and imaging findings are non-specific. Therefore it is imperative to carefully consider the patient’s medical history, systemic examination findings, pathological biopsy findings and immunohistochemistry to diagnose middle ear anaplastic large T-cell lymphoma at an early stage.

Key words: Middle ear, Tumor, Anaplastic large T cell lymphoma, Immunocombination chemistry, Otology surgery

CLC Number: 

  • R764.92
[1] 文锋, 王冰洁, 扈希昊, 等. 咽淋巴环套细胞淋巴瘤4例及文献复习[J]. 山东大学耳鼻喉眼学报, 2020,34(1): 115-120. doi: 10.6040/j.issn.1673-3770.0.2019.490. WEN Feng, WANG Bingjie, HU Xihao, et al. Mantle cell lymphoma involving the Waldeyer's ring: a case series and literature review[J]. J Otolaryngol Ophthalmol Shandong Univ, 2020, 34(1): 115-120. doi: 10.6040/j.issn.1673-3770.0.2019.490.
[2] 杨国溜, 陈良远, 欧巧萍. 外周血EB病毒DNA与非霍奇金淋巴瘤的预后相关性研究[J]. 国际检验医学杂志, 2020,41(3): 290-292,296. doi: CNKI:SUN:GWSQ.0.2020-03-009. YANG Guoliu, CHEN Liangyuan, OU Qiaoping. Study on the relationship between Epstein-Barr virus DNA and prognosis of non-Hodgkin's lymphoma[J]. Int J Lab Med, 2020,41(3): 290-292,296. doi: CNKI:SUN:GWSQ.0.2020-03-009.
[3] Chihara D, Fanale MA. Management of anaplastic large cell lymphoma[J]. Hematol Oncol Clin North Am, 2017, 31(2): 209-222. doi:10.1016/j.hoc.2016.11.001.
[4] Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011[J]. Am J Hematol, 2015, 90(9): 790-795. doi:10.1002/ajh.24086.
[5] Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States[J]. J Clin Oncol, 2016, 34(9): 963-971. doi:10.1200/JCO.2015.63.5540.
[6] Box JK, Paquet N, Adams MN, et al. Nucleophosmin: from structure and function to disease development[J]. BMC Mol Biol, 2016, 17(1): 19. doi:10.1186/s12867-016-0073-9.
[7] Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The pathological spectrum of systemic anaplastic large cell lymphoma(ALCL)[J]. Cancers(Basel), 2018, 10(4): E107. doi:10.3390/cancers10040107.
[8] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi:10.1182/blood-2016-01-643569.
[9] Mora J, Filippa DA, Thaler HT, et al. Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center[J]. Cancer, 2000, 88(1): 186-197. doi:10.1002/(sici)1097-0142(20000101)88: 1<186: aid-cncr26>3.0.co;2-5.
[10] Stein H, Foss HD, Dürkop H, et al. CD30(+)anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features[J]. Blood, 2000, 96(12): 3681-3695. doi: 10.1053/beha.2000.0100.
[11] King RL, Dao LD, McPhail ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements[J]. Am J Surg Pathol, 2016, 40(1): 36-43. doi:10.1097/PAS.0000000000000500.
[12] Shustov A, Soma L. Anaplastic large cell lymphoma: contemporary concepts and optimal management[J]. Cancer Treat Res, 2019, 176: 127-144. doi:10.1007/978-3-319-99716-2_6.
[13] Agnelli L, Mereu E, Pellegrino E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma[J]. Blood, 2012, 120(6): 1274-1281. doi:10.1182/blood-2012-01-405555.
[14] Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry[J]. Hematol Oncol, 2015, 33(4): 120-128. doi:10.1002/hon.2153.
[15] 陈英坤, 俞文娟, 刘辉, 等. 原发系统型间变性大细胞淋巴瘤40例临床特征及预后分析[J]. 中华血液学杂志, 2020(3): 222-227. doi: 10.3760/cma.j.issn.0253-2727.2020.03.007. Chen Yingkun, Yu Wenjuan, Liu Hui, et al. Clinical features and prognosis analysis of 40 cases of primary systemic anaplastic large cell lymphoma[J]. Chinese Journal of Hematology, 2020(3): 222-227. doi: 10.3760/cma.j.issn.0253-2727.2020.03.007.
[16] Allen CE, Kelly KM, Bollard CM. Pediatric lymphomas and histiocytic disorders of childhood[J]. Pediatr Clin North Am, 2015, 62(1): 139-165. doi:10.1016/j.pcl.2014.09.010.
[17] Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project[J]. Blood, 2008, 111(12): 5496-5504. doi:10.1182/blood-2008-01-134270.
[18] Ceccon M, Merlo MEB, Mologni L, et al. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency[J]. Oncogene, 2016, 35(29): 3854-3865. doi:10.1038/onc.2015.456.
[19] Zeng Y, Feldman AL. Genetics of anaplastic large cell lymphoma[J]. Leuk Lymphoma, 2016, 57(1): 21-27. doi:10.3109/10428194.2015.1064530.
[20] Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma[J]. Blood, 2015, 126(1): 17-25. doi:10.1182/blood-2014-10-567461.
[21] 何健, 钱立庭, 高劲. 外耳道腺样囊性癌侵犯中耳、颞叶且伴颈部淋巴结转移一例报告[J]. 山东大学耳鼻喉眼学报, 2018,32(6): 109-111,118. doi: 10.6040/j.issn.1673-3770.0.2017.424. HE Jian, QIAN Liting, GAO Jin. A case of external auditory canal adenoid cystic carcinoma invading the middle ear and temporal lobe, with cervical lymph node metastasis[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018,32(6): 109-111,118. doi: 10.6040/j.issn.1673-3770.0.2017.424.
[22] Thakral B, Zhou J, Medeiros LJ. Extranodal hematopoietic neoplasms and mimics in the head and neck: an update[J]. Hum Pathol, 2015, 46(8): 1079-1100. doi:10.1016/j.humpath.2015.05.007.
[23] Alqunaee M, Aldaihani A, AlHajery M. Non-Hodgkin's lymphoma of the middle ear presenting as mastoiditis[J]. Case Rep Otolaryngol, 2018, 2018: 7639784. doi:10.1155/2018/7639784.
[24] 孟琳, 姜妍, 余晔. 中耳恶性淋巴瘤一例[J]. 听力学及言语疾病杂志, 2020,28(6): 725-727. doi: 10.3969/j.issn.1006-7299.2020.06.027.
[25] Tram Do B, Charpentier AM, Bourré-Tessier J, et al. Unusual presentation for small lymphocytic lymphoma: Case report of a man with bilateral ear involvement and review of the literature[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2019, 136(3S): S45-S47. doi:10.1016/j.anorl.2018.10.017.
[26] Danino J, Joachims HZ, Ben-Arieh Y, et al. T cell lymphoma of the ear presenting as mastoiditis[J]. J Laryngol Otol, 1997, 111(9): 852-854. doi:10.1017/s0022215100138794.
[27] Li B, Liu SX, Yang H, et al. Primary T-cell lymphoblastic lymphoma in the middle ear[J]. Int J Pediatr Otorhinolaryngol, 2016, 82: 19-22. doi:10.1016/j.ijporl.2015.12.020.
[28] Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+diffuse large B cell lymphoma[J]. Am J Hematol, 2013, 88(9): 798-802. doi:10.1002/ajh.23467.
[29] Hart S, Horsman JM, Radstone CR, et al. Localised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience(1971-2000)[J]. Clin Oncol(R Coll Radiol), 2004, 16(3): 186-192. doi:10.1016/j.clon.2003.10.010.
[30] Jackson R, Addison AB, Prinsley PR. Cholesteatoma in children and adults: are there really any differences?[J]. J Laryngol Otol, 2018, 132(7): 575-578. doi:10.1017/S0022215118000890.
[31] Yung M, Tono T, Olszewska E, et al. EAONO/JOS joint consensus statements on the definitions, classification and staging of middle ear cholesteatoma[J]. J Int Adv Otol, 2017, 13(1): 1-8. doi:10.5152/iao.2017.3363.
[32] 杨扬, 肖潇, 陈敏, 等. 儿童中耳胆脂瘤JOS分期及其临床特征[J]. 山东大学耳鼻喉眼学报, 2019,33(05), 33: 52-55. doi: 10.6040/j.issn.1673-3770.0.2019.376. YANG Yang, XIAO Xiao, CHEN Min, et al. JOS staging and clinical features of middle ear cholesteatoma in children[J]. J Otolaryngol Ophthalmol Shandong Univ, 2019,33(05), 33: 52-55. doi: 10.6040/j.issn.1673-3770.0.2019.376.
[33] Gomaa MA, Abdel Karim AR, Abdel Ghany HS, et al. Evaluation of temporal bone cholesteatoma and the correlation between high resolution computed tomography and surgical finding[J]. Clin Med Insights Ear Nose Throat, 2013, 6: 21-28. doi:10.4137/CMENT.S10681.
[34] Wallis S, Atkinson H, Coatesworth A P. Chronic otitis media[J]. Postgrad Med, 2015, 127(4): 391-395. doi: 10.1080/00325481.2015.1027133.
[35] Jaisinghani VJ, Paparella MM, Schachern PA, et al. Tympanic membrane/middle ear pathologic correlates in chronic otitis media[J]. Laryngoscope, 1999, 109(5): 712-716. doi:10.1097/00005537-199905000-00007.
[36] 杨昌秀. 46例中耳胆脂瘤的临床特征及手术疗效分析[J]. 现代临床医学, 2020, 46(6): 425-428. doi:10.11851/j.issn.1673-1557.2020.06.009. YANG Changxiu. Clinicalfeature and operative effect of 46 cases of middle ear of cholesteatoma[J]. J Mod Clin Med, 2020, 46(6): 425-428. doi:10.11851/j.issn.1673-1557.2020.06.009.
[37] Ayache D, Darrouzet V, Dubrulle F, et al. Imaging of non-operated cholesteatoma: clinical practice guidelines[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2012, 129(3): 148-152. doi:10.1016/j.anorl.2011.09.005.
[38] Mileshina NA, Kurbatova EV. Cholesteatoma of the external and middle ear in the childhood[J]. Vestn Otorinolaringol, 2015(1): 25-27. doi:10.17116/otorino201580125-27.
[39] Yates PD, Flood LM, Banerjee A, et al. CT scanning of middle ear cholesteatoma: what does the surgeon want to know?[J]. Br J Radiol, 2002, 75(898): 847-852. doi:10.1259/bjr.75.898.750847.
[40] Mittal R, Lisi CV, Gerring R, et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media[J]. J Med Microbiol, 2015, 64(10): 1103-1116. doi:10.1099/jmm.0.000155.
[41] Filipe M, Reimer Å, Matuschek E, et al. Fluoroquinolone-resistant Alcaligenes faecalis related to chronic suppurative otitis media, Angola[J]. Emerg Infect Dis, 2017, 23(10): 1740-1742. doi:10.3201/eid2310.170268.
[42] Varshney S, Nangia A, Bist SS, et al. Ossicular chain status in chronic suppurative otitis media in adults[J]. Indian J Otolaryngol Head Neck Surg, 2010, 62(4): 421-426. doi:10.1007/s12070-010-0116-3.
[43] Majeed J, Sudarshan Reddy L. Role of CT mastoids in the diagnosis and surgical management of chronic inflammatory ear diseases[J]. Indian J Otolaryngol Head Neck Surg, 2017, 69(1): 113-120. doi:10.1007/s12070-016-1023-z.
[44] Brennan-Jones CG, Head K, Chong LY, et al. Topical antibiotics for chronic suppurative otitis media[J]. Cochrane Database Syst Rev, 2020, 1: CD013051. doi:10.1002/14651858.CD013051.pub2.
[45] Gendeh HS, Abdullah AB, Goh BS, et al. Intracranial complications of chronic otitis media: why does it still occur?[J]. Ear Nose Throat J, 2019, 98(7): 416-419. doi:10.1177/0145561319840166.
[46] Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study[J]. Blood, 2015, 126(1): 36-41. doi:10.1182/blood-2014-12-616961.
[47] 刘丁丁, 钱晓云, 刘永泽, 等. 84例原发头颈部淋巴瘤临床及病理特征分析[J]. 山东大学耳鼻喉眼学报, 2018,32(6): 48-51. doi: 10.6040/j.issn.1673-3770.0.2018.274. LIU Dingding, QIAN Xiaoyun, LIU Yongze, et al. Analysis of clinical and pathological features of 84 patients with primary head and neck lymphoma[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018,32(6): 48-51. doi: 10.6040/j.issn.1673-3770.0.2018.274.
[48] Cederleuf H, Bjerregård Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study[J]. Br J Haematol, 2017, 178(5): 739-746. doi:10.1111/bjh.14740.
[49] Ganesan P, Joshua T, Sundersingh S, et al. Refractory ALK-positive anaplastic large cell lymphoma: long term survival with crizotinib[J]. Indian J Hematol Blood Transfus, 2018, 34(2): 353-354. doi:10.1007/s12288-017-0889-6.
[50] Vu K, Ai WY. Update on the treatment of anaplastic large cell lymphoma[J]. Curr Hematol Malig Rep, 2018, 13(2): 135-141. doi:10.1007/s11899-018-0436-z.
[51] Piccaluga PP, Fuligni F, de Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study[J]. J Clin Oncol, 2013, 31(24): 3019-3025. doi:10.1200/JCO.2012.42.5611.
[52] Wilhelm M, Smetak M, Reimer P, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation[J]. Blood Cancer J, 2016, 6(7): e452. doi:10.1038/bcj.2016.63.
[53] Dhawale TM, Shustov AR. Autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas: a histology-specific review[J]. Hematol Oncol Clin North Am, 2017, 31(2): 335-357. doi:10.1016/j.hoc.2016.11.003.
[54] Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma[J]. Blood, 2017, 130(25): 2709-2717. doi:10.1182/blood-2017-05-780049.
[55] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study[J]. J Clin Oncol, 2016, 34(23): 2698-2704. doi:10.1200/jco.2015.65.9789.
[56] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol, 2017, 10(1): 69. doi:10.1186/s13045-017-0439-6.
[57] Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma[J]. Blood, 2018, 131(4): 397-407. doi:10.1182/blood-2017-09-806737.
[58] Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168): 229-240. doi:10.1016/s0140-6736(18)32984-2.
[59] Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma[J]. J Clin Oncol, 2020, 38(32): 3794-3804. doi:10.1200/JCO.20.01342.
[1] WEN Liting, LI Xu, GAO Wei, HU Tianyong, ZENG Xianhai, ZHA Dingjun. An analysis of the clinical characteristics of delayed facial paralysis following middle ear surgery [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 1-5.
[2] GONG Xiaoyang, LI Wang, CHEN Xi. Retrospective analysis of 67 cases of primary parapharyngeal space tumors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 60-65.
[3] ZHANG Lijun, XU Ran, LUO Jifang, LIU Guoqi, HE Qian, LI Wei, JIANG Zhenhua. Factors affecting flap neurosis and other postoperative flap-related complications after free-flap reconstruction of head and neck tumors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 86-90.
[4] WANG MeiOverview,LI ZhihaiGuidance. Laryngeal cancer stem cells: potential therapeutic targets for overcoming multidrug resistance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 120-128.
[5] CHEN Jiahong, WANG Lin, JIANG Yan, YU Longgang, ZHANG Jisheng, ZHANG Zhiyong, KONG Jingwen. Primary extraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumor in the nasal cavity and paranasal sinus: a case report and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 290-296.
[6] YANG Yang, WANG Xiaoxu, ZHANG Jie. Progress on diagnosis and treatment of middle ear cholesteatoma in children [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 1-6.
[7] LI Ling, LI Cong, SUN Yan, CHEN Liang. A case of an infant with embryonal rhabdomyosarcoma in the middle ear and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 55-59.
[8] CHEN Kun, LU Hui, HUANG Qi, LI Lei, MENG Guozhen, YANG Jun, HOU Dongming. Clinical diagnosis and treatment of congenital nasal sinus mass in children [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 81-85.
[9] WAN Yining, ZHANG Dejun, FU Zeming, GUO Fang, GUO Yingyuan, GUAN Guofang. Diffusion-weighted imaging for accurate diagnosis of congenital middle ear cholesteatoma and JOS staging [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 65-69.
[10] WANG JunxinOverview,SUN YanGuidance. Research progress of miRNA-29b involved in EMT-related signaling pathway regulation [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 132-137.
[11] ZHANG Xiaoyan, HAO XiaofengOverview,XIE LikeGuidance. The application and progress of optical coherence topography in choroidal osteoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(6): 138-141.
[12] JIN Xin, SHI Lei, JIN Mengyuan. Application of decellularized dermal matrix after benign tumor resection in the nasal sinus [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 17-22.
[13] SHEN Nimei, QIAN Maohua, JIN Jiaxin, QIN Yang, WANG Jun, WU Ying, GAO Gang. Application of the ultrasonic scalpel in tonsillectomy for biopsy of patients with suspected tonsillar tumor [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 62-66.
[14] LI Yanjie, JIA Jian, YANG Ping, WAN Baoluo. Study on the value of tumor abnormal protein in clinical diagnosis of laryngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 70-74.
[15] FAN HuijuanOverview,ZHANG HailiGuidance. Advancements of HIF-1α and VEGF in middle ear cholesteatoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 93-97.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] HE Shou-huan,CHEN Bin,YIN Shan-kai,SU Kai-ming,JIANG Xiao . Morphological changes of the upper airway in OSAHS patients with UPPP
[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(5): 385 -388 .
[2] SONG Xi-cheng,ZHANG Qing-quan,XIA Yong-hong,LIU Lu-yi, YU Lu-xin,WANG Gao,JIANG Xiu-liang . Post-operative ICU monitoring and nursing for patients with OSAHS[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(5): 389 -392 .
[3] XUE Wei-guo,SUN Jie,JIN Zheng,SHI Wen-bin,XIN Lu,LIN Guo-Jing,LI Jia-yun . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(4): 300 -303 .
[4] ZHANG Qing-quan,LI Xin-min,WANG Qiang,WANG Yong-fu . Some experience of the endoscopy treatment of maxillary sinus lesion with the canine tooth fossa approach[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2007, 21(1): 38 -39 .
[5] DONG Pin,LI Xiao-yan,TU Li-qiang,MENG Qing-hong,WANG Sang,XIE Jin,JIANG Yan . Reconstruction for advanced hypopharyngeal carcinoma and laryngeal recurrent carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2007, 21(5): 385 -387 .
[6] JIANG Shao-hong,ZHU Yu-hong,WANG Qiang,SONG Xi-cheng . Intractable primary epistaxis: a report of 101 cases[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2007, 21(6): 542 -544 .
[7] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(1): 74 -77 .
[8] LEIXun, LIU Qianghe, KONG Zhongyu, XIANG Qiu, GENG WANping, HUANG Hui, DONG Yiyuan, LIU Fangxian. ARelationship between expression of Survivin and radiosensitization effect of EGCG in xenotransplanted nasopharyngeal carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2009, 23(1): 6 -9 .
[9] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2009, 23(2): 73 -74 .
[10] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(01): 29 -33 .